FridayApr 21, 2017 1:21 pm

Epilepsy Patients are the New Focus of ChineseInvestors.com, Inc.’s (CIIX) CBD Health Products

In China, there are close to 10 million epilepsy patients, the Chinese Overseas Medical Advisory Service Center estimates. There is no cure in the country, although risky surgery is sometimes performed in the U.S., where there are over three million people living with epilepsy. Many patients rely on Chinese herbs for temporary control. However, ChineseInvestors.com’s (OTCQB: CIIX) current development plan includes making cannabidiol (CBD) products available online for people with epilepsy and Alzheimer’s disease. Its online store (ChineseCBDoil.com) and Yelp-style mobile application are helping to serve Chinese-speaking consumers around the world, and investors as well, with a reach into the…

Continue Reading

WednesdayApr 19, 2017 9:00 am

After Ten Thousand Years and Countless Uses, Cannabis Still Has a Bright Future

CBDWire Editorial Coverage: When George Washington cultivated cannabis at his estate in Mt. Vernon, he was continuing a tradition that dates back 10,000 years. There are indications that cannabis sativa, grown as hemp, was farmed for its fiber content in Neolithic times. Since then, numerous uses have been discovered. As hemp, the plant has furnished a variety of commercial and industrial products. Hemp seeds are also edible, as they are high in protein and are a rich source of vitamins, minerals and dietary fiber. And with 483 distinct chemical compounds, 66 of which are cannabinoids, the uses to which cannabis…

Continue Reading

TuesdayApr 18, 2017 11:19 am

SinglePoint, Inc. (SING) Maximizes Upside Potential and Limits Downside Risk

Owning shares of a holding company often times can provide unique opportunities to profit from non-traditional markets with great upside potential. SinglePoint, Inc. (OTC: SING), a publicly traded holding company, offers just such non-traditional upside opportunity with its foray into the burgeoning cannabis market. Traditionally, SinglePoint has focused on mobile technology and mobile marketing by offering client-based solutions for business transactions, donations and targeted communications. The company connects client companies to target markets by providing innovative mobile technology at reasonable rates. However, SinglePoint recognized the strength and profit potential in acquiring interest in undervalued, high-growth entities in disparate markets to…

Continue Reading

ThursdayApr 13, 2017 3:26 pm

India Globalization Capital, Inc. (NYSE: IGC) Plans to Develop Cannabinoid Extract Therapies for Cats and Dogs

India Globalization Capital, Inc. (NYSE MKT: IGC) intends to become a “first-mover” in developing cannabis-based combination therapies for large market conditions such as pain, eating disorders, refractory epilepsy, and seizures. In addition, IGC has filed two patents, IGC-502 and IGC-505, for combination therapies for the treatment of seizures in dogs and cats, which in it itself is a surprisingly large market. It is believed that abnormal brain activity is the cause of most seizures in dogs and cats. These seizures can be either violent or subtle. Some seizures may occur just once, but others can be repeated and require treatment…

Continue Reading

WednesdayApr 12, 2017 2:47 pm

ChineseInvestors.com, Inc. (CIIX) Eyes Germany’s Growing Medical Hemp Market

ChineseInvestors.com, Inc. (OTCQB: CIIX) attended the ‘Invest 2017’ exhibition in Stuttgart, Germany, on April 7-8, 2017, anticipating that the conference would be an opportunity for CIIX to introduce its hemp companies and products to German investors, but CIIX is not alone in seeing the growth opportunities for medical cannabis in that market. CIIX operates a website for Chinese-speaking investors. It has also opened, in the Shanghai Free Trade Area, a store that distributes CBD health oil products to the global Chinese-speaking population. Germany permits the use of medical marijuana, and it recently further loosened its regulations. Earlier this year, the…

Continue Reading

WednesdayApr 12, 2017 8:30 am

Marijuana Industry Growth Fueled by Investments and Public Support for Legalization

The number of states in which the medical and recreational use of marijuana is legal continues to grow. Medical marijuana is now permitted in 28 states and Washington D.C. Last year, the North American legal marijuana industry grew to $6.7 billion, a 34 percent increase in just one year, according to Arcview Market Research. With the black market included, sales topped $56 billion. Public support is increasing as well – 57 percent of Americans supported the legalization of marijuana in 2016, up from 52 percent in 2014 (1). With the market expanding and public support increasing, there are more opportunities…

Continue Reading

TuesdayApr 11, 2017 12:22 pm

The Value Drivers of InMed Pharmaceuticals, Inc. (IMLFF)

The cannabis plant is comprised of, among other things, phytochemicals that have evolved over time to become very biologically active. Most of the current research and development (R&D) surrounding cannabis revolves around understanding these biologically-active ingredients, especially cannabinoids. To date, over 90 cannabinoids have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for distinctive pharmacological effects. The cannabinoids that bind more selectively to certain receptors have become more desirable for medical usage because of the advantage offered. Examples of phytochemicals that have been developed into pharmaceutical drugs include the bronchodilator (asthma), salicin (aspirin) and a number…

Continue Reading

MondayApr 10, 2017 9:13 am

InMed Pharmaceuticals, Inc. (IMLFF) Offers More than Just a Non-THC Cannabinoid Drug Pipeline

Now that 28 states have passed comprehensive medical marijuana laws, conditions have never looked better for expanding research and development (R&D) into the therapeutic benefits of cannabinoids, which is exactly what InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is doing. Its efforts have already borne results: the company has two novel drug candidates in its pipeline. But there’s more to InMed than meets the eye; the Vancouver, Canada-based company has developed a proprietary process to manufacture cannabinoids based on biosynthesis. In addition, it has constructed an algorithm to identify the cannabinoids most likely to have beneficial therapeutic effect. With this…

Continue Reading

FridayApr 07, 2017 12:28 pm

Player’s Network, Inc. (PNTV) – Using Unique Business Models to Increase Revenue

Player’s Network, Inc. (OTCQB: PNTV) is a fully reporting diversified holdings company, operating in two main industries: medical marijuana and media. The company’s primary objective is to create shareholder value by identifying opportunities in niche emerging markets. PNTV has three prominent subsidiaries: Next Gen TV, WeedTV.com, and Green Leaf Farms, all of which operate under profitable business models. The primary goal for WeedTV.com is to generate revenues from its proprietary channels and clients. Proprietary channels that Player’s Network is able to generate revenues through include membership subscriptions, advertising, and cross-selling with other organizations. In addition to this, the company’s Next…

Continue Reading

FridayApr 07, 2017 9:21 am

India Globalization Capital, Inc. (NYSE: IGC) at the Forefront of Innovation Thanks to Strategic Alliances

How does a company in the mining industry successfully move toward becoming a leader in the marijuana sector, specifically cannabinoid-based pharmaceutical therapies that treat a variety of diseases and conditions? In the case of India Globalization Capital, Inc. (NYSE MKT: IGC), the answer is creative management’s ability to identify opportunity, coupled with a relentless drive toward innovation. IGC made its switch to the marijuana industry after its CEO, Executive Chairman, and President Ram Mukunda was unafraid to recognize and act on a need for the company to make a positive and swift switch to a stronger and more lucrative market.…

Continue Reading

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722